|
Role of primary surgery for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Roche |
Consulting or Advisory Role - Roche |
Speakers' Bureau - AstraZeneca; Roche |
Travel, Accommodations, Expenses - Roche; Teva |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - PharmaMar; Tesaro |
Consulting or Advisory Role - Advaxis; AstraZeneca; Genmab; Pfizer; Roche/Genentech |